Sri Priya Ranganathan, Indian Ambassador to Korea (left), and Cha Jeong-hak, CEO of Humasis, signed a contract for the supply of COVID-19 diagnostic kits to India.

Sri Priya Ranganathan, Indian Ambassador to Korea (left), and Cha Jeong-hak, CEO of Humasis, signed a contract for the supply of COVID-19 diagnostic kits to India.

View original image

[Asia Economy Reporter Eunmo Koo] Humasis, a multi-quantitative in vitro diagnostics specialist company, will export its novel coronavirus disease (COVID-19) diagnostic kits to India.


On the 20th, Humasis visited the Embassy of India in Korea and announced on the 21st that it had signed a supply contract for 500,000 tests of its COVID-19 antibody rapid diagnostic kit product, the ‘COVID-19 IgG/IgM Test’.


This contract is the first case in which the Embassy of India in Korea directly signed a contract between an Indian government agency and a Korean company. It is known to be a contract for delivery to the Indian Council of Medical Research (ICMR), a related agency of the Indian government.


The Embassy of India in Korea stated, “This cooperation is an important part of efforts to strengthen India’s diagnostic capabilities in the fight against the COVID-19 pandemic,” adding, “It also aligns with the promise made by the heads of both countries to consult, support, and share experiences to eradicate COVID-19.”


Cha Jung-hak, CEO of Humasis, said, “We hope that the export of this diagnostic kit will help respond to the COVID-19 situation locally, even if just a little,” and added, “We will do our best to consult with each other in various fields in the future to respond more quickly to special situations.”



Humasis is responding to requests for about 3 million tests from 30 countries, including Brazil, Germany, the United Kingdom, France, Italy, Poland, Kazakhstan, Indonesia, and the Philippines, where contracts and sales are already underway, as well as India. Accordingly, the company plans to actively respond by increasing production capacity, such as introducing new fully automated equipment necessary for diagnostic kit production earlier this year, to ensure no disruption in supply.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing